EGFR and non-small cell lung carcinoma: Moreover, although the benefits of adjuvant chemotherapy are modest, in the ADAURA trial, the HR for 2-year DFS was superior in patients who received adjuvant chemotherapy vs. those who did not (0.16 vs. 0.23), suggesting some incremental benefit of chemotherapy in addition to osimertinib, further confirming that, at least with the evidence available so far, adjuvant chemotherapy remains a standard of care for chemo-eligible patients affected by resected EGFR mutant NSCLC, in cases prior to TKIs.